SPBPB8B6.03 Antibody

What is SPBPB8B6.03 and why is it important for research?

SPBPB8B6.03 is a gene in Schizosaccharomyces pombe (fission yeast) that encodes the Sup11p protein. This protein shows significant homology to Saccharomyces cerevisiae Kre9 and is involved in β-1,6-glucan synthesis, which is critical for cell wall formation. Sup11p is indispensable for proper septum assembly, and research has shown that the sup11+ gene is essential for cell viability. When expression of sup11+ is reduced, β-1,6-glucan becomes absent from the cell wall, leading to severe morphological defects and malformation of the septum with massive accumulation of cell wall material .

Research implications include:

• Understanding fundamental cell wall biology in fungi

• Identifying potential targets for antifungal drug development

• Studying protein O-mannosylation mechanisms

• Examining conserved biological processes between yeast and higher eukaryotes

What are the recommended methods for generating antibodies against SPBPB8B6.03/Sup11p?

Several methodological approaches are recommended:

Recombinant antibody generation:

• Use synthetic peptides or recombinant protein fragments from conserved regions of Sup11p

• Employ HuCAL® recombinant monoclonal antibody library technology, which uses phage display to generate fully human Fab and immunoglobulin formats

• Express the target protein in E. coli with appropriate tags for immunization

Hybridoma development workflow:

• Immunize mice, rats, hamsters, rabbits, chickens, goats, or alpacas with purified recombinant Sup11p

• Isolate B cells and fuse with myeloma cells to create hybridomas

• Screen hybridomas for specific antibody production using ELISA

• Select high-affinity clones using multiple validation methods

• Scale production using hollow fiber bioreactors for mg to gram scale yields

How should I choose between polyclonal and monoclonal antibodies for SPBPB8B6.03 research?

YCharOS testing has demonstrated that recombinant antibodies are significantly more effective and reproducible than polyclonal antibodies, especially when validated with knockout cell lines .

How can I thoroughly validate an antibody against SPBPB8B6.03/Sup11p to ensure reproducibility?

Apply the "five pillars" of antibody characterization recommended by the International Working Group for Antibody Validation :

• Genetic strategies:

  • Generate SPBPB8B6.03 knockout or knockdown yeast strains

  • Use CRISPR-Cas9 to create cell lines lacking the target

  • Employ conditional expression systems (e.g., nmt81-sup11 knock-down mutant)

• Orthogonal strategies:

  • Compare antibody-based detection with mass spectrometry

  • Correlate protein levels with RNA-seq data

  • Use GFP-tagged Sup11p expressed from its native locus

• Independent antibody strategies:

  • Use multiple antibodies targeting different epitopes of Sup11p

  • Compare results from different antibody formats (Fab, scFv, IgG)

  • Validate across different antibody vendors or production methods

• Recombinant expression strategies:

  • Overexpress tagged versions of Sup11p in yeast

  • Create standard curves with purified recombinant protein

  • Use inducible expression systems to modulate protein levels

• Immunocapture MS strategies:

  • Perform immunoprecipitation followed by mass spectrometry

  • Identify all proteins captured by the antibody

  • Confirm specific enrichment of Sup11p compared to controls

What specific epitope selection strategies should I consider for generating SPBPB8B6.03 antibodies?

Based on the Sup11p protein structure, consider these strategic approaches:

Structural epitope mapping:

• Target the conserved domains shared between Sup11p and Kre9 for antibodies with cross-reactivity potential

• Use computational modeling to identify surface-exposed regions with high antigenicity

• Employ epitope scaffolding techniques similar to those used for viral proteins

Region-specific targeting:

• N-terminal epitopes: May be useful for detecting secreted forms of Sup11p

• S/T-rich regions: These highly O-mannosylated regions are characteristic of Sup11p

• Functional domains: Target regions critical for β-1,6-glucan synthesis

• Species-specific regions: Select unique sequences for S. pombe-specific detection

For optimal epitope selection, prioritize:

• Regions with low post-translational modifications (avoid heavily glycosylated areas unless specifically targeting glycoforms)

• Sequences with limited homology to other proteins

• Solvent-accessible regions based on structural predictions

• Areas with low sequence variation if cross-species reactivity is desired

How should I develop an effective immunoassay to measure SPBPB8B6.03/Sup11p in complex samples?

A comprehensive assay development strategy includes:

Sample preparation optimization:

• Develop proper cell lysis buffers that preserve Sup11p structure (consider detergent types and concentrations)

• Establish spheroblasting protocols optimized for S. pombe

• Include appropriate protease inhibitors to prevent Sup11p degradation

• Test different methods for membrane protein solubilization

Assay format selection based on research goals:

• Western blot: For protein size confirmation and semi-quantitative analysis

• ELISA: For quantitative measurement in solution

• Immunofluorescence: For localization studies

• Flow cytometry: For cell-by-cell analysis

• Immunoprecipitation: For protein-protein interaction studies

Key optimization parameters to consider:

• Antibody concentration (perform titration experiments)

• Blocking reagent selection (BSA vs. milk vs. commercial blockers)

• Incubation times and temperatures

• Detection system sensitivity (chemiluminescence vs. fluorescence)

• Controls (positive, negative, isotype, knockout samples)

For yeast cell wall studies, consider specialized techniques like:

• Cell wall biotinylation followed by antibody detection

• Proteinase K protection assays to distinguish surface vs. internal protein

• EndoH treatment to assess glycosylation status

How can I use SPBPB8B6.03 antibodies for studying protein-protein interactions in the yeast cell wall?

Several advanced methodological approaches can be employed:

Co-immunoprecipitation strategies:

• Cross-link protein complexes in vivo using cell-permeable cross-linkers

• Lyse cells under native conditions that preserve protein-protein interactions

• Immunoprecipitate Sup11p using validated antibodies

• Identify binding partners through mass spectrometry

• Confirm interactions using reciprocal co-IP with antibodies against putative partners

Proximity labeling techniques:

• Express Sup11p fused to BioID or APEX2 to biotinylate proximal proteins

• Capture biotinylated proteins using streptavidin

• Identify proximal proteins by mass spectrometry

• Validate findings using your SPBPB8B6.03 antibody for co-localization studies

Super-resolution microscopy applications:

• Use directly-labeled antibodies for STORM or PALM imaging

• Visualize nanoscale distribution of Sup11p within the cell wall

• Perform multi-color imaging with markers for other cell wall components (β-1,3-glucan, α-1,3-glucan)

• Quantify spatial relationships between Sup11p and other septum components

Consider adapting techniques from studies of Bgs1p, Bgs3p, and Bgs4p localization during the cell cycle for Sup11p research.

What are the best practices for using SPBPB8B6.03 antibodies in live cell imaging experiments?

For successful live cell imaging with antibodies against Sup11p:

Antibody fragment preparation:

• Generate and validate Fab or scFv fragments from your full IgG

• Confirm epitope recognition is maintained in the smaller format

• Label fragments with bright, photostable fluorophores (Alexa Fluor series)

• Validate that labeling doesn't interfere with binding

Cell preparation considerations:

• Optimize cell wall permeabilization methods that maintain cell viability

• Consider using protoplasts for improved antibody accessibility

• Use microfluidics systems for controlled antibody delivery

• Maintain physiological conditions throughout imaging

Advanced imaging strategies:

• Use ratiometric indicators (like roGFP2) for quantitative measurements

• Employ FRAP (Fluorescence Recovery After Photobleaching) to study dynamics

• Implement single-particle tracking to monitor Sup11p movement

• Consider lattice light-sheet microscopy for reduced phototoxicity in long-term imaging

Critical controls:

• SPBPB8B6.03 knockout/knockdown cells

• Non-binding antibody fragments of the same format

• Carefully matched fluorophore concentrations for quantitative comparisons

• Pre-absorption controls with recombinant protein

How can I leverage SPBPB8B6.03 antibodies for studying cell cycle-dependent changes in protein localization?

Based on research showing that Sup11p is involved in septum formation and cell wall synthesis , consider these approaches:

Synchronized cell population analysis:

• Synchronize S. pombe cultures using temperature-sensitive cdc mutants or elutriation

• Sample cells at defined timepoints throughout the cell cycle

• Perform immunofluorescence using optimized SPBPB8B6.03 antibodies

• Quantify changes in localization patterns relative to cell cycle markers

• Correlate with septum formation using calcofluor white staining

Live-cell time-lapse imaging:

• Use cell cycle phase markers (e.g., SPB proteins) in combination with Sup11p antibody fragments

• Track individual cells through division

• Quantify protein dynamics during septum formation and cell separation

• Compare with known septum-associated proteins like Bgs1p, Bgs3p, and Bgs4p

Cell cycle arrest experiments:

• Use hydroxyurea (S-phase), latrunculin (cytokinesis), or MBC (mitosis) to arrest cells

• Examine Sup11p localization at specific arrest points

• Compare with transcriptomic data on cell-cycle dependent expression

From published data on septum formation, you would expect Sup11p to be recruited to the division site during cytokinesis, similar to how Bgs3p localizes to growing poles during interphase and to the septum during cytokinesis .

How should I analyze seemingly contradictory results when using different SPBPB8B6.03 antibodies?

When faced with contradictory results:

Systematic antibody characterization:

• Assess each antibody's target epitope (are they binding different regions of Sup11p?)

• Validate specificity using knockout/knockdown controls

• Test for cross-reactivity with similar proteins

• Evaluate performance across multiple assay conditions

Common sources of discrepancy to investigate:

• Different antibody formats (polyclonal vs monoclonal vs recombinant)

• Varied epitope accessibility in different assays

• Protocol-specific differences (fixation methods, detergents, blocking agents)

• Post-translational modifications affecting epitope recognition

• Antibody lot-to-lot variation

Resolution approaches:

• Use orthogonal detection methods to validate findings

• Perform genetic rescue experiments with tagged versions of Sup11p

• Consider that both results may be correct under different conditions

• Explore if discrepancies reveal unknown biology (protein isoforms, conformational changes)

Remember that approximately 50% of commercial antibodies fail to meet basic characterization standards, potentially leading to $0.4-1.8 billion in annual losses due to unreliable research .

What statistical approaches should I use when quantifying SPBPB8B6.03 expression across different experimental conditions?

For robust statistical analysis:

Data normalization strategies:

• Normalize to housekeeping proteins (Actin, GAPDH) for Western blots

• Use total protein normalization methods (Ponceau, REVERT stains)

• Apply geometric mean normalization when using multiple reference genes

• Consider spike-in controls for absolute quantification

Statistical test selection based on experimental design:

• Two conditions: t-test (parametric) or Mann-Whitney (non-parametric)

• Multiple conditions: ANOVA with appropriate post-hoc tests

• Repeated measures: Paired tests or mixed-effects models

• Dose-response: Regression analysis or specialized curve-fitting

Advanced approaches for complex experiments:

• Use hierarchical models for nested experimental designs

• Apply bootstrapping for improved confidence interval estimation

• Implement Bayesian analysis for incorporating prior knowledge

• Consider machine learning for pattern recognition in localization data

Minimum reporting recommendations:

How can I interpret changes in SPBPB8B6.03/Sup11p localization and abundance during cell wall stress?

Based on research on cell wall synthesis and stress response:

Expected patterns under cell wall stress:

• Increased Sup11p expression during cell wall damage (similar to other cell wall synthesis proteins)

• Potential relocalization to sites of active cell wall remodeling

• Changes in post-translational modifications (especially glycosylation patterns)

• Altered protein-protein interactions within cell wall synthesis complexes

Analytical framework for interpretation:

• Compare changes in Sup11p with other cell wall proteins (Bgs1-4, Gas1-5)

• Correlate protein changes with transcriptomic data

• Examine temporal dynamics of the response (immediate vs. delayed)

• Assess if changes are stress-specific or general

Functional validation approaches:

• Generate mutants with altered Sup11p regulation

• Test sensitivity of these mutants to cell wall stressors

• Perform epistasis analysis with other cell wall synthesis genes

• Use chemical genetics to target specific pathways

Consider that transcriptome analysis of nmt81-sup11 mutants showed significant regulation of several cell wall glucan modifying enzymes , suggesting a complex regulatory network that responds to perturbations in Sup11p levels.

What troubleshooting steps should I take when SPBPB8B6.03 antibodies fail to detect protein in S. pombe lysates?

Follow this systematic troubleshooting workflow:

Sample preparation optimization:

• Test different lysis methods (mechanical disruption, enzymatic spheroblasting)

• Try various buffer compositions (different detergents, salt concentrations)

• Add protease inhibitors to prevent degradation

• Include reducing agents if disulfide bonds might affect epitope accessibility

• Consider that Sup11p is likely membrane-associated and may require specialized extraction

Antibody-specific considerations:

• Confirm antibody reactivity with recombinant Sup11p protein

• Test different antibody concentrations (5-10× higher than standard protocols)

• Try alternative detection methods (more sensitive substrates, amplification systems)

• Consider epitope retrieval methods if applicable

• Use a positive control antibody against a known S. pombe protein

Technical adjustments:

• Increase protein loading amount

• Extend primary antibody incubation time and optimize temperature

• Test different membrane types for Western blotting (PVDF vs. nitrocellulose)

• Modify blocking conditions (BSA vs. milk, concentration, time)

• Try using shorter transfer times or a different transfer buffer

Remember that Sup11p is O-mannosylated , which may affect antibody recognition, and consider using deglycosylation treatments before analysis.

How can I optimize immunoprecipitation protocols specifically for SPBPB8B6.03/Sup11p?

For successful Sup11p immunoprecipitation:

Buffer optimization strategy:

• Test multiple lysis buffers with varying detergent types (digitonin, NP-40, CHAPS, DDM)

• Optimize salt concentration to maintain specific interactions (150-500 mM NaCl range)

• Include stabilizing agents (glycerol, specific ions) that maintain protein conformation

• Consider adding specific protease inhibitor cocktails optimized for yeast

Antibody coupling approaches:

• Direct coupling to beads: Covalently attach antibodies to activated supports (NHS-agarose)

• Indirect methods: Use Protein A/G beads to capture antibody-antigen complexes

• Oriented coupling: Use biotinylated antibodies with streptavidin supports

• Tag-based alternatives: Consider epitope tagging Sup11p if antibody IP is inefficient

IP protocol enhancements:

• Pre-clear lysates to reduce non-specific binding

• Use gentle washing conditions to preserve weak interactions

• Elute with epitope peptide for native complex recovery

• Consider cross-linking to stabilize transient interactions

• For membrane proteins like Sup11p, include longer solubilization steps

Validation and controls:

• Input, unbound, wash, and eluate samples should be analyzed

• IgG isotype control to establish baseline non-specific binding

• Knockout/knockdown samples as negative controls

• Competition with recombinant Sup11p or epitope peptide

What specialized protocols exist for studying the post-translational modifications of SPBPB8B6.03/Sup11p?

Based on research showing Sup11p undergoes O-mannosylation and potentially N-glycosylation :

Glycosylation analysis workflow:

• Generate lysates in buffers preserving glycan structures

• Treat separate aliquots with:

  • PNGase F (removes N-linked glycans)

  • Endo H (removes high-mannose N-glycans)

  • O-glycosidase (removes O-linked glycans)

  • α-mannosidase (specifically removes mannose residues)

• Analyze migration patterns by Western blot using SPBPB8B6.03 antibodies

• Perform lectin blotting in parallel to confirm glycan composition

Mass spectrometry approaches:

• Enrich for glycopeptides using lectin affinity chromatography

• Use electron transfer dissociation (ETD) to preserve PTM attachments

• Implement glycoproteomics workflows with specialized fragmentation techniques

• Compare wild-type Sup11p with protein expressed in glycosylation-deficient strains

Site-specific modification analysis:

• Generate antibodies specific to modified forms of Sup11p

• Perform site-directed mutagenesis of potential modification sites

• Use proximity labeling to identify enzymes responsible for Sup11p modifications

• Correlate modifications with protein localization and function

Research has shown that Sup11p is hypo-mannosylated when expressed in an O-mannosylation mutant background, and can be N-glycosylated on an unusual N-X-A sequon located inside an S/T-rich region that is normally highly O-mannosylated .